Latest News

Small Cap Wrap – Amryt Pharma

0

Small Cap Feast – 29 October 2020

Dish Of The Day:

SourceBio International (SBI.L) has listed on AIM raising £35m.  Services include Healthcare Diagnostics, Genomics, Stability Storage and infectious Disease Testing – since May 2020, the Group has provided COVID-19 Antigen RT-PCR testing services.  £120m market cap.

Zinnwald Resources (ZNWD.L) has listed on AIM following a Reverse Takeover by Erris Resources. · Completed acquisition of 50% interest in late stage high return Zinnwald Lithium Project: €428m pre-tax NPV (8% discount rate); Pre-Tax IRR 27.4%; 46% EBITDA margin (Feasibility Study). · Plan to advance the Project towards becoming a supplier of high value lithium products to Europe’s rapidly growing EV (electric vehicle) and energy storage markets. £3.75m placing.

 

Off The Menu:

No Leavers Today

 

What’s Cooking In The IPO Kitchen?

Verici DX—developer of advanced clinical diagnostics for organ transplant, intends to apply to have its issued share capital, as enlarged by a proposed placing, subscription . The Restricted Offer is only available to certain persons, being persons who held the beneficial title to any A Shares of £0.001 each in the capital of the Company on 10 July 2020 (the “Record Date”) whose registered address is in the UK  (being persons recorded on the register of members of Renalytix AI plc on 9 July 2020). £14.5m fundraise. Mkt Cap c.£28.3m. Due 3 November

SDIC Holdings a leading power generation company in China is to list on the standard segment of the Official List and to trading on the Shanghai-London Stock Connect segment of the main market for listed securities of London Stock Exchange. Due on or around 22 Oct. Gross proceeds from the Offering are expected to amount to between approximately USD 220 million and USD 240 million. The proceeds will be used for expanding the Group’s renewable energy business overseas and repaying the Group’s offshore indebtedness.

Round Hill Music Royalty fund to IPO on the Specialist Fund Segment of the Main Market of the London Stock Exchange, by way of a placing and offer for subscription targeting the issue of 375 million ordinary shares  at an issue price of US$1.00 per Ordinary Share.  The Company’s Investment Objective is to provide investors with an attractive level of regular and growing income and capital returns from investment primarily in high quality, music intellectual property.  Due mid-November.

Meritwell II intends to list on the Specialist Funds Segment of the LSE raising up to £250m. The Placing will provide UK institutions with the opportunity to “swap” illiquid holdings which have become time and resource consuming holdings, at their bid price, in return for ordinary shares in the Company. Due 26 Oct.

Mailbox REIT PLC , a newly formed single asset company which owns the Mailbox , a large prime office-led mixed use property in Birmingham which has been independently valued at £179m, announced its intention to raise up to £62.5m  MailBox REIT  will apply for the Ordinary Shares be admitted to trading  on the IPSX Prime segment of International Property Securities Exchange (IPSX ).   IPSX is a new Regulated Investment Exchange regulated by the FCA and is the world’s first such exchange dedicated to the initial public offering and secondary market trading of companies owning single institutional grade real estate assets and multiple assets with commonality. Due  November.

Tirupati Graphite, the fully-integrated, cash generative, specialist graphite and graphene producer with operations in Madagascar and India, announced its potential intention to undertake an initial public offering on the LSE (standard listing). Timing tbc

Umuthi Healthcare Solutions Plc, the technology led healthcare business focused on the distribution of pharmaceuticals and the provision of medical facilities in remote areas, seeking admission to the Standard Listing segment of the Official List.  Timing tbc

Kibo Energy PLC (AIM:KIBO), the multi-asset Africa focused energy Company, is seeking admission for its 100% owned UK subsidiary Sloane Developments Ltd , which will be renamed Mast Energy Developments PLC (MED), to the Standard List of the London Stock Exchange plc. Targeted for Q4 2020. The MED business strategy is to acquire and develop a portfolio of flexible small-scale power generation assets, exploiting a growth niche market in the UK for Reserve Power generation to balance out the national grid at critical times.  

 

Breakfast Buffet

Zoltav Resources 40.5p £57.5m (AIM:ZOL)

The Russia-focused oil and gas exploration and production company, announced results for the six months ended 30 June 2020.

Revenues declined by 12% to RUB 552 million (USD 8 million) (H1 2019: RUB 624 million (USD 9.6 million)), due mainly to lower gas production and lower oil and condensate prices. · Operating profit of RUB 87.2 million (USD 1.26 million) (H1 2019: operating loss of RUB 105 million (USD 1.61 million)). Total cash at the end of the period was RUB 31 million (USD 0.45 million) (H1 2019: RUB 330 million (USD 5.33 million)) .

“H1 2020 was a busy period operationally, completing, in tandem, both the substantial feasibility study programme on East Bortovoy and continuing the development drilling programme on West Bortovoy.

We continue to work to maximise the potential of the western fields, with the work programme expected to enable Zoltav to deliver sustainable gas production of at least 35.3 mmcf/d (1 mmcm/d) by the end of 2020. At the same time, we are considering options for the potential development of the eastern fields on the Bortovoy Licence. This project remains subject to a final investment decision.”

 

Escape Hunt 9.25p £7.4m (AIM)

Escape Hunt, a global leader in the growing escape rooms sector, announced  the opening of its next UK owner-operated site based in Basingstoke today, having opened for bookings on 15th October 2020. It is the eleventh UK site operating under the ‘Escape Hunt’ brand and will have six games rooms, including an instance of Escape Hunt’s newest Doctor Who themed game, ‘A Dalek Awakens’ as well as a virtual reality games room.  Outdoor games are also available.

 

Alpha Financial Markets Consulting 215p £229m (AIM:AFM)

Alpha FMC, a leading global provider of specialist consultancy services to the asset and wealth management industry, today announces the launch of its dedicated Environmental, Social and Governance (ESG) and Responsible Investment (RI) practice. The practice will comprise a global network of 20+ ESG practitioners; most of whom are already working with clients, on ESG & RI programmes.

 

Kape Technologies 160p £257m (LON:KAPE)

Completion of $115m fund raise vs initial target of $100m by the digital security and privacy software business at 150p.    The net proceeds of the Placing and Retail Offer will be used as follows:

o  c. US$72 million to buy out the equity interests in the Company of Andrew Lee and Steven DeProspero (the “PIA Founders”), the two co-founders of Private Internet Access (“PIA”), a company acquired by Kape in 2019; and

o  the balance to strengthen Kape’s balance sheet and enable fast execution of further selective acquisitions, building on Kape’s excellent M&A track record and continuing pursuit of growth.

 

Marlowe 547p £300m (AIM:MRL)

Further to the announcement of 28 October 2020 of the acquisition of Ellis Whittam and a proposed placing, Marlowe (specialist services group focused on developing companies which assure safety and regulatory compliance) has successfully raised approximately £30 million before expenses under the Placing, which was oversubscribed. The Placing Price of 547 pence per share represents a nil discount to the closing price on 28 October 2020.

 

Panthera Resources 12.25p £10.4m (LON:PAT)

The diversified gold exploration and development company with assets in West Africa and India, announced that fieldwork at its Bassala Project has now commenced.

 Highlights

Ground magnetic surveying now underway with soil sampling to commence shortly

Programme to define and rank drill targets for testing during H1 2021

Processed results from ground magnetic survey due by early November 2020

High-grade intersections from previous drilling and artisanal workings

Located within 5-8km of Kalana (Endeavour, 4Moz) of Kodieran (Wassoul’or, 2Moz) mines

“Our shareholders now have exposure to seven highly prospective gold projects in four countries. Eight of nine assets in the Panthera portfolio have ore grade mineralisation evidenced through historical shallow mining activity and six of these projects have deeper ore grade drilling intersections.”

 

MTI Wireless Edge 45p £39.84m (AIM:MWE)

The technology group focused on comprehensive communication and radio frequency solutions across multiple sectors, announced that the St Petersburg office of MTI Summit has secured a significant order for delivery in 2021 from a Russian customer. The contract is worth approximately US$1.5 million and is a repeat order for the supply of radio frequency components.  

 

Amryt Pharma 208p £339m (AIM:AMYT)

The commercial-stage biopharmaceutical company dedicated to developing and commercialising novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, announced positive results from its pivotal Phase 3 EASE trial of FILSUVEZ® (Oleogel-S10/previously AP101). Further to Amryt’s announcement of September 9, 2020, the Company today releases additional data which will be presented as a late-breaking oral presentation on behalf of the trial investigators by Professor Dedee Murrell (Chair, Department of Dermatology, St George Hospital, UNSW, Sydney, Australia) at the 29th EADV (European Association of Dermatology and Venereology) Virtual Congress 2020 on October 31, 2020.

The primary endpoint of the trial was met with statistical significance

The proportion of patients with first complete closure of EB target wound within 45 days was 41.3% in the Oleogel-S10 group and 28.9% in the control group (p value=0.013)

This translates to a 44% increase in the probability of target wound closure with Oleogel-S10 compared to the control gel

The proportion of Recessive Dystrophic EB (“RDEB”) patients with first complete closure of EB target wound within 45 days was 44.0% in the Oleogel-S10 group and 26.2% in the control group (nominal p value=0.008)

This translates to a 72% increase in the probability of target wound closure with Oleogel-S10 compared to the control gel in RDEB patients

 

Proactis Holdings 31.5p £30.1m (AIM:PHD)

The business spend management solution provider, today announces its audited results for the financial year ended 31 July 2020.

Record year in new business total contract value (“TCV”) signed up 29% to £14.6m (2019: £11.3m)

Annualised recurring revenue (“ARR”), excluding heightened risk accounts (“HRAs”), increased by 1.3% to £39.8m (31 July 2019: £39.3m)

Excluding the impact of the COVID-19 global pandemic (“COVID-19”) on volume-related contracts, underlying ARR grew by 8.0% · ARR including HRAs was £41.2m (2019: £44.3m)

Reported revenues of £49.6m (2019: £54.1m) reflective of prior year new business / churn performance

Adjusted EBITDA of £11.8m (2019: £15.1m), in line with market expectations · Adjusted EPS 2.9p (2019: 6.6p)

Impairment of £14.8m taken against French and German Cash Generating Units (“CGUs”) as a result of changes in the Group’s reporting structure and in the US CGU as a result of the impact of COVID-19 in volume related businesses.

Reported loss before tax £19.3m (2019: £25.8m)

Net bank debt of £37.1m (31 January 2020: £35.6m)

Reset banking facilities with HSBC in order to support the Group’s current business plan for the mid-term

Post period -Strategic new business wins in DE and FR . Early adopters identified for bePayd platform

 

Biome Tech 155p £5.7m (AIM:BIOM)

The  bioplastics and radio frequency technology business, today provides a trading update for the nine months ended 30 September 2020. Revenues in the Bioplastics division in Q3 at £1.6m were 48% ahead of the previous quarter (Q2 2020: £1.1m) and 131% ahead of the prior year comparative (Q3 2019: £0.7m). Revenues in the RF Technologies division in Q3 were £0.2m (Q3 2019: £0.6m), resulting in revenues in the first nine months of the financial year of £0.6m (2019: £2.8m).  The fibre optic cable market, normally a major driver of the business, remains impacted by both over-capacity and COVID-19 disruption. The division continues to make a concerted effort to increase its geographic footprint and range of applications and already benefits from recurring revenue from power generation, medical and general industrial markets. The business has continued to win small projects in the UK induction heating and welding market, but overall demand remains subdued.

Total Group revenues in Q3 were £1.8m (2019: £1.3m) taking Group revenues for the nine months to 30 September 2020 to £4.3m (2019: £4.7m). It is to be noted that all revenue figures in this statement exclude grant income (£38,000 in the third quarter of this year and £124,000 for the nine months).  Costs and capital expenditure continue to be managed tightly and as the Government furlough scheme ends in October, activity levels are such that staff are returning to normal duties. The Group’s cash position as at 30 September 2020 was £0.9m (30 June 2020: £1.1m) and the Group had no debt.

Appointment of Robert (Rob) Smith to the Board of the Company as Group Chief Financial Officer (CFO), effective 30 November 2020.  Most recently Rob served in the CFO and CEO roles at Filtronic PLC, an AIM listed electronics designer and manufacturer of advanced filters, antennas and transceivers.

 

Head Chef:

Derren Nathan
0203 764 2344
[email protected]

*A corporate client of Hybridan LLP

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email [email protected] with “unsubscribe me”.

Genel Energy says operator DNO highlights production increase at Tawke PSC in Kurdistan

Previous article

FTSE 100 show late promise but ends flat; US stocks rebound on GDP growth

Next article

You may also like

Comments

Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News